Treatments in Endocrinology

, Volume 4, Issue 6, pp 389–389 | Cite as

Once-Monthly Ibandronate

A Viewpoint by Stuart Silverman
  • Stuart Silverman
Adis Drug Profile Guest Commentary


  1. 1.
    Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856–61PubMedCrossRefGoogle Scholar
  2. 2.
    Cramer JA, Amonker MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. In pressGoogle Scholar
  3. 3.
    Siris ES, Rosen CJ, Harris ST, et al. Adherence rates to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis [abstract no. 397]. The Sixth International Symposium on Osteoporosis: Current Status and Future Directions, the National Osteoporosis Foundation; 2005 Apr 6–10; Washington (DC)Google Scholar
  4. 4.
    Simon JA, Beusterien KM, Hebborn A, et al. Bisphosphonate dosing preferences in women with postmenopausal osteoporosis: a study. The Female Patient 2004; 30: 31–6Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Stuart Silverman
    • 1
  1. 1.Cedars-Sinai/University of CaliforniaLos Angeles, Beverly HillsUSA

Personalised recommendations